Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    Animal Pharm   
Email ID
Password
Forgotten password?
Sign me in automatically next time
Home
Product Sector
Regulatory Region
Pre-marketing Regulation
Post-marketing Regulation
Healthcare Systems
Legal
Pharmaceuticals
|
Biologics
|
Advanced Therapies
|
Combination Products
|
Veterinary
|
MedTech
|
Diagnostics
|
Scrip Regulatory Affairs
Refining the benefit-risk framework for assessing medicines: valuing and weighting the parameters
23 February 2011
Stuart Walker, James Neil McAuslane, Lawrence Liberti
Please login to read the full article.
 
Not a subscriber ?  
 
 
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
FEATURES
Regulatory Affairs Pharma Features
COMMENT
Other Informa Comments
   
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Product Sector
Regulatory Region
Pre-marketing Regulation
Post-marketing Regulation
Healthcare Systems
Legal
Terms &Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Clinica
Scrip
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm